Novel cosmetic or dermatological composition containing a live probiotic bacterial strain

Abstract

The present invention relates to a cosmetic or dermatological composition comprising at least one live probiotic bacterial strain and at least one fat-dispersible and fat-soluble linear molecule selected from any one of dicaprylyl carbonate, coco caprylate, coco caprate, undecane and / or tridecane, linoleic acid, behenyl alcohol or a mixture thereof, wherein the total content of the fat-dispersible and fat-soluble linear molecule is at least 40% by weight based on the total weight of the composition. The present invention also relates to the use of a fat-dispersible and fat-soluble linear molecule selected from any one of dicaprylyl carbonate, coco caprylate, coco caprate, undecane and / or tridecane, linoleic acid, behenyl alcohol or a mixture thereof for maintaining the viability of the live probiotic bacterial strain in the composition for topical administration.

Description

Technical Field

[0001] The present invention belongs to the field of dermatological or cosmetic compositions containing a probiotic bacterial strain and at least one linear lipid-soluble and fat-dispersible molecule of at least 40% by weight and their use.

Background Art

[0002] Probiotics have been recognized as useful for topical application to the skin. Thus, beneficial effects of probiotics on the skin have been reported in various clinical studies not only in the field of cosmetics but also in dermatology. Probiotics are actually beneficial as cosmetic ingredients (M. Rahmati Roudsari et al., Health Effects of Probiotics on the Skin, Crit. Rev. Food. Sci. Nutr., 2015, 55(9), 1219 - 40). The use of probiotics may also be great in the prevention and treatment of skin diseases, particularly eczema, atopic dermatitis, acne and allergic inflammation. Other uses include treatment of skin hypersensitivity, treatment of skin damage by ultraviolet rays and wound protection.

[0003] However, due to technical problems related to the nature of this type of product, there are few probiotic products available on the market for topical application. The main problem is to maintain the viability of the probiotics in the composition while preventing the growth of the probiotics not only during the manufacturing period of the composition but also during the storage period of the composition. This is because most conventional cosmetic and / or dermatological formulations cause a loss of viability of the probiotics during manufacturing and / or storage due to the presence of compounds that are particularly harmful or bactericidal to bacteria. Conversely, in the absence of these compounds, especially in aqueous formulations, the probiotics grow and storage becomes impossible.

[0004] Furthermore, the topical composition must enable sufficient retention of the probiotics on the skin over a long period, which is not possible with conventional formulations [Garima Sharma, Manuhaar Sharma, Rishav Sood, Jayanthi Neelamraju, Suvarna G. Lakshmi, Ratna Sudha Madempudi, Praveen Rishi and Indu Pal Kaur (2021); Self-Preserving Gelatin Emulgel Containing Whole Cell Probiotic for Topical Use: Preclinical Safety, Efficacy, and Germination Studies, Expert Opinion on Drug Delivery, 18, 11, 1777-1789].

[0005] These issues are hindering the use of probiotics by topical application, particularly in the fields of cosmetology and dermatology.

Summary of the Invention

Problems to be Solved by the Invention

[0006] Accordingly, the present invention aims to solve this technical problem by providing a composition that replenishes the skin with probiotics by topical application in a safe, effective, and practical manner, and enables the thus formulated probiotics to locally improve skin health and / or beauty.

[0007] Solutions already exist in these fields, but they have drawbacks such as overly strict prescription and application constraints and are insufficient. Thus, solutions for the application of probiotics by microneedles, patches or encapsulation are described (WO 2020127637A1 pamphlet; Hui-Jiuan Chen et al., Transdermal Delivery of Living and Biofunctional Probiotics through Dissolvable Microneedle Patches, ACS Applied Bio Materials, 2018, 1(2), 374-381). Oil-based gels containing oil and an oily viscous agent are also described (WO 2020 / 249734A1 pamphlet).

Means for Solving the Problems

[0008] In this regard, unexpectedly and surprisingly, the Applicant has found that a composition for topical application, particularly for cosmetic and / or dermatological applications, containing at least 40% by weight of linear lipophilic and fat-dispersible molecules, at least one of which is selected from specifically selected linear lipophilic and fat-dispersible molecules and optionally combined with one or more other linear fat-dispersible and lipophilic molecules, makes it possible to solve this technical problem in a safe, simple, reliable, practical and efficient way.

[0009] This is because the Applicant has found that the use of one or more specifically selected linear lipophilic and fat-dispersible molecules, optionally combined with one or more other linear fat-dispersible and lipophilic molecules, at a total minimum content of linear lipophilic and fat-dispersible molecules of at least 40% by weight relative to the total weight of the composition intended for topical application such as a cosmetic and / or dermatological composition, maintains the viability of live probiotic bacteria and thus makes it possible to solve this technical problem.

[0010] The linear lipophilic and fat-dispersible molecules according to the invention that are specifically selected are - dicaprylyl carbonate, - coco caprylate optionally combined with coco caprate, preferably a mixture of coco caprylate and coco caprate, - undecane and / or tridecane, - linoleic acid and / or oleic acid and / or their linear esters (e.g., isostearyl linoleate) and / or oleyl alcohol, - behenyl alcohol and / or its acid and ester derivatives, especially behenic acid, also known as docosanoic acid or docosanoic acid ester or behenic acid ester, and / or any one of their mixtures selected from.

[0011] Linear fat-soluble and fat-dispersible molecules have been conventionally used in cosmetic and / or dermatological compositions for their skin-softening properties. However, when these molecules, especially the selected ones, are present at a minimum content of 40% by weight based on the total weight of the cosmetic and / or dermatological composition, unlike other fat-soluble and fat-dispersible molecules described in the prior art, especially branched molecules, it has not been known to be possible to maintain the viability of living bacteria contained in this composition, and thus to solve the problems of the prior art. This is because the examples show that branched-chain fatty substances cannot sufficiently maintain the viability of bacteria in the absence of the selected linear fat-soluble and fat-dispersible molecules.

[0012] Therefore, the present invention makes it possible to develop locally applicable cosmetic and / or dermatological compositions that provide stability in a particularly advantageous manner, and in particular provide the long-term viability of probiotics without their growth over a satisfactory period that meets the constraints of distribution and storage in the fields of cosmetics and dermatology. Therefore, in these compositions, the probiotic bacterial strain is stable, i.e., the strain remains alive, does not grow excessively, and thus remains in a stable state until it is used.

[0013] As demonstrated in the examples, such a composition according to the invention remains stable and, in particular, advantageously, - at ambient temperature, i.e. at a temperature of 18 °C to 25 °C, in particular approximately 21 °C, for at least 3 months, and - at 4 °C for 16 months, in fact even up to 18 months, the viability and preservability of the probiotic bacterial strains contained therein are maintained.

[0014] The linear lipophilic and fat-dispersible molecules used are oils or waxes and can thus formulate the probiotic bacterial strains into a formulation that is anhydrous or contains little water, so that there is no need to rely on preservatives that reduce and destroy the viability of the probiotic bacteria.

[0015] Furthermore, the composition according to the invention is easy to apply and can be easily formulated, unlike the solutions described in the prior art.

[0016] The subject of the present invention is - at least one live probiotic bacterial strain, and - at least one linear fat-dispersible and lipophilic molecule selected from dicaprylyl carbonate; coco-caprylate optionally combined with coco-caprate, preferably a mixture of coco-caprylate and coco-caprate; undecane and / or tridecane; linoleic acid and / or oleic acid and / or their linear esters and / or oleyl alcohol; behenyl alcohol and / or its acid and ester derivatives, in particular behenic acid or docosanoic acid or behenic acid ester; and / or a mixture thereof, and - optionally, one or more other linear fat-dispersible and lipophilic molecules and a cosmetic and / or dermatological composition, the total content of the linear fat-dispersible and lipophilic molecules being at least 40% by weight relative to the total weight of the composition.

[0017] In particular, in the cosmetic and / or dermatological composition according to the invention, the other linear fat-dispersible and lipophilic molecules are - An alkane molecule with the chemical formula C n H 2n+2 (wherein n represents a value in the range of 6 to 40), - An ester molecule with the chemical formula CH3-C x H 2x -COO-C y H 2y -CH3 (wherein each of the exponents x and y independently represents a value in the range of 5 to 19), - An acid molecule with the chemical formula CH3-C x H 2x -C(O)OH (wherein x represents a value in the range of 5 to 24, preferably 5 to 21), for example, cerotic acid, - An alcohol molecule with the chemical formula CH3-C x H 2x -OH (wherein x represents a value in the range of 5 to 21), and any one of their mixtures is selected from.

[0018] In particular, in the cosmetic and / or dermatological composition according to the invention, a linear fat-dispersible and liposoluble molecule selected from dicaprylyl carbonate; coco-caprylate optionally combined with coco-caprate, preferably a mixture of coco-caprylate and coco-caprate; undecane and / or tridecane; linoleic acid and / or oleic acid and / or their linear esters and / or oleyl alcohol; behenyl alcohol and / or its acid and ester derivatives, in particular behenic acid or docosanoic acid or behenic acid ester; and / or a mixture thereof is present in a content of at least 8% by weight, preferably at least 10% by weight, more preferably at least 15% by weight based on the total weight of the composition.

[0019] In particular, in the cosmetic and / or dermatological composition according to the invention, the linear fat-dispersible and liposoluble molecule is dicaprylyl carbonate.

[0020] In particular, in the cosmetic and / or dermatological composition according to the invention, the selected linear fat-dispersible and liposoluble molecule is capricaprylate, optionally combined with coco-caprate, preferably a mixture of coco-caprylate and coco-caprate.

[0021] In particular, in the cosmetic and / or dermatological composition according to the invention, the selected linear fat-dispersible and liposoluble molecule is dicaprylyl carbonate.

[0022] In particular, in the cosmetic and / or dermatological composition according to the invention, the selected linear fat-dispersible and liposoluble molecules are undecane and / or tridecane.

[0023] In particular, in the cosmetic and / or dermatological composition according to the invention, the selected linear fat-dispersible and liposoluble molecules are linoleic acid and / or oleic acid and / or isostearyl linoleate and / or oleyl alcohol, preferably linoleic acid.

[0024] In particular, in the cosmetic and / or dermatological composition according to the invention, the selected linear fat-dispersible and liposoluble molecules are behenyl alcohol and / or its acid and ester derivatives, in particular behenic acid or docosanoic acid or behenic acid ester, preferably behenyl alcohol or docosanol.

[0025] In particular, in the cosmetic and / or dermatological composition according to the invention, the linear fat-dispersible and liposoluble molecule selected from dicaprylyl carbonate; capricaprylate, optionally combined with coco-caprate, preferably a mixture of coco-caprylate and coco-caprate; undecane and / or tridecane; linoleic acid and / or oleic acid and / or their linear esters and / or oleyl alcohol; behenyl alcohol and / or its acid and ester derivatives, in particular behenic acid or docosanoic acid or behenic acid ester; and / or mixtures thereof is present in a content of at least 40% by weight, preferably at least 50% by weight, more preferably at least 60% by weight, based on the total weight of the composition.

[0026] In particular, the cosmetic and / or dermatological composition according to the invention comprises at least two, preferably three or four linear fat-dispersible and fat-soluble molecules selected from dicaprylyl carbonate; coco-caprylate optionally combined with coco-caprate, preferably a mixture of coco-caprylate and coco-caprate; undecane and / or tridecane; linoleic acid and / or oleic acid and / or their linear esters and / or oleyl alcohol; behenyl alcohol and / or its acid and ester derivatives, in particular behenic acid or docosanoic acid or behenic acid ester.

[0027] In particular, the cosmetic and / or dermatological composition according to the invention further comprises branched-chain fat-soluble and fat-dispersible molecules selected from octyldodecanol, propylheptyl caprylate, a mixture of caprylyl triglyceride and capric triglyceride, hydrogenated castor oil, shea butter, coconut oil and / or coco-glyceride.

[0028] In particular, in the cosmetic and / or dermatological composition according to the invention, the live probiotic bacterial strain is selected from Lactobacillus crispatus, Corynebacterium accolens, Sphingomonas glacialis, Streptococcus salivarus and mixtures thereof.

[0029] In particular, in the cosmetic and / or dermatological composition according to the invention, the live bacterial strain is incorporated in an amount ranging from 10% to 80% by weight, preferably from 30% to 70% by weight, more preferably from 40% to 60% by weight, based on the total weight of the powder obtained by lyophilization on a maltodextrin support.

[0030] In particular, in the cosmetic and / or dermatological composition according to the invention, the viable bacterial strain has a content of 10 3 to 10 15 CFU (colony forming units) per gram of the composition.

[0031] In particular, in the cosmetic and / or dermatological composition according to the invention, the viable bacterial strain has a content of 0.01% to 3% by weight based on the total weight of the composition.

[0032] In particular, in the cosmetic and / or dermatological composition according to the invention, the water activity (Aw) in the composition is less than 0.6.

[0033] In particular, the cosmetic and / or dermatological composition according to the invention is in the form of an oily suspension or solution, an oily cream or gel, an emulsion, water-in-oil type, or multiple type, or silicone type emulsion, a mask, a beauty liquid, a lotion, a solid soap, a solid shampoo, a solid foam product, a dermatological bar, an ointment, a mousse, a patch, for example in the form of a makeup powder, a rod or a stick, preferably in the form of a liquid, pasty or solid anhydrous product.

[0034] The invention further relates to the non-therapeutic use of the cosmetic composition according to the invention for preventing and / or reducing the aesthetic and / or unpleasant symptom manifestations of healthy skin, healthy body surface growths and / or healthy mucous membranes, in particular sensitive or sensitized skin, body surface growths and / or mucous membranes, fragile or weakened skin, body surface growths and / or mucous membranes, dry skin, body surface growths and / or mucous membranes and / or skin, body surface growths and / or mucous membranes having an atopic tendency.

[0035] The invention further relates to the non-therapeutic use of the cosmetic composition according to the invention as a moisturizing agent and / or a soothing agent for healthy skin, healthy body surface growths and / or healthy mucous membranes.

[0036] In particular, the non-therapeutic use according to the invention is preferably carried out by topical application to healthy skin, mucosa and / or sites of body surface growths selected from the leg; foot; underarm; hand; thigh; waist; buttocks; waist; groin; inguinal region; abdomen; collar lapel; neck; arm; torso; back; in particular the face including the forehead, cheek, nose, temple, T-zone (forehead, nose and chin), external auditory canal and / or jaw; scalp; hair; nails; and / or oral mucosa, preferably the underarm, collar lapel, hair, nails, oral mucosa and / or face, more preferably the face.

[0037] The present invention further relates to the use of dicaprylyl carbonate; coco caprylate optionally combined with coco caprate, preferably a mixture of coco caprylate and coco caprate; undecane and / or tridecane; linoleic acid and / or oleic acid and / or their linear esters and / or oleyl alcohol; behenyl alcohol and / or its acids and ester derivatives, in particular behenic acid or docosanoic acid or behenic acid esters; and / or mixtures thereof, selected from at least one linear fat-dispersible and fat-soluble molecule, and optionally one or more other linear fat-dispersible and fat-soluble molecules, wherein the total weight of the linear fat-dispersible and fat-soluble molecules is at least 40% by weight based on the total weight of the cosmetic and / or dermatological composition.

[0038] The Applicant has also discovered that a composition according to the invention containing at least one live probiotic bacterial strain can thus be used as a cosmetic composition for improving the appearance and / or comfort of healthy skin, in particular healthy scalp and / or mucosa and / or healthy body surface growths, in particular hair and nails, and / or for the cosmetic care of healthy skin and / or mucosa and / or healthy body surface growths including the most delicate skin, such as healthy skin having a sensitive, sensitized, fragile, weakened, dry and / or atopic tendency. The linear lipophilic and fat-dispersible molecules selected are preferably skin softeners that make it possible to improve the hydration of the skin and / or mucosa and / or to soften them.

[0039] Another subject of the present invention is for the cosmetic treatment of sensitive healthy skin and / or healthy mucous membranes, sensitized healthy skin and / or healthy mucous membranes, fragile and / or weakened healthy skin and / or healthy mucous membranes, healthy skin and / or healthy dry mucous membranes, healthy skin and / or healthy mucous membranes having an atopic tendency, and / or as a sedative or a moisturizer, applying the cosmetic composition according to the invention topically to at least one site of healthy skin and / or mucous membranes and / or healthy body surface growths. A beauty care method characterized by including the step.

[0040] The applicant has also found that the compositions according to the invention, in particular dermatological compositions, are useful in the treatment and / or prevention of infections of the skin, mucous membranes and / or body surface growths caused by pathogenic microorganisms such as S. aureus, in particular fungal diseases such as eczema, seborrheic or atopic dermatitis, acne and skin or mucous membrane inflammations and / or erythemas caused by pathogenic bacteria such as S. aureus, in particular in the treatment and / or prevention of diaper rash in infants, and / or in the prevention and / or pharmaceutical treatment, in particular dermatological treatment, of conditions associated with reactive and / or atopic skin. Therefore, these compositions according to the invention are useful for the dermatological care of infant skin for the prevention of atopic and / or reactive skin and / or diaper rash in infants.

[0041] Accordingly, the subject matter of the present invention is a dermatological composition according to the invention for use as an anti-inflammatory or antibacterial composition and / or in the treatment and / or prevention of skin and / or mucosal infections, such as mycosis or S. aureus infections, such as eczema, dandruff, seborrheic or atopic dermatitis, acne and skin or mucosal inflammations caused by pathogenic bacteria, such as S. aureus, such as mycosis, S. aureus infections and / or erythema, in particular in the treatment and / or prevention of diaper rash in infants and / or in the prevention and / or pharmaceutical treatment of conditions associated with reactive and / or atopic skin, in particular in dermatological treatment.

[0042] In particular, the present invention relates to a dermatological composition according to the invention for use as an anti-inflammatory or antibacterial agent and / or in the treatment of infections of the skin, and / or mucosa, and / or cutaneous growths caused by pathogenic yeasts or bacteria, such as pathogenic microorganisms such as S. aureus, such as mycosis, eczema, seborrheic or atopic dermatitis, acne and skin or mucosal inflammations caused by pathogenic yeasts or bacteria, such as pathogenic microorganisms such as S. aureus, and / or erythema, in particular in the treatment and / or prevention of diaper rash in infants and / or in the prevention and / or pharmaceutical treatment of conditions associated with reactive and / or atopic skin and / or mucosa, in particular in dermatological treatment.

[0043] Another subject of the present invention is a method for treating and / or preventing skin and / or mucosal infections particularly associated with pathogenic microorganisms such as yeasts or bacteria, such as mycosis or S. aureus infections, such as eczema, dandruff, seborrheic or atopic dermatitis, acne and skin or mucosal inflammation and / or erythema caused by pathogenic bacteria such as S. aureus, and / or particularly diaper rash in infants, and / or preventing and / or pharmaceutically treating conditions associated with reactive and / or atopic skin, particularly dermatological treatment, in a patient in need thereof, the method comprising administering to the patient a pharmaceutically or dermatologically effective amount of the skin composition according to the present invention.

[0044] Another subject of the present invention is for the treatment and / or prevention of infections of the skin, and / or mucosa, and / or cutaneous growths caused by pathogenic yeasts or bacteria, such as pathogenic microorganisms such as S. aureus, such as mycosis, eczema, seborrheic or atopic dermatitis, acne and skin or mucosal inflammation and / or erythema caused by pathogenic yeasts or bacteria, such as pathogenic microorganisms such as S. aureus, and / or particularly diaper rash in infants, and / or for the prevention and / or pharmaceutical treatment, particularly dermatological treatment, of conditions associated with reactive and / or atopic skin and / or mucosa, the use of the dermatological composition according to the present invention for preparing an anti-inflammatory composition and / or an antibacterial composition and / or a medicament.

[0045] The composition according to the present invention is preferably intended for topical administration.

DETAILED DESCRIPTION OF THE INVENTION

[0046] In the context of the present invention, the terms "cosmetic use" and / or "cosmetic composition" are understood to mean non-medical use and / or composition, i.e., those not intended for therapeutic use, applied to "healthy" parts of the body, particularly "healthy" areas of the skin.

[0047] In the context of the present invention, the term "healthy skin and / or mucosa" means a site of human skin and / or mucosa to which the agent or composition according to the present invention is applied and which is termed "non-pathological" by a dermatologist, i.e., does not exhibit an infection, scar, skin disease or skin condition such as candidiasis, impetigo contagiosa, psoriasis, eczema, inflammation, ichthyosis, acne vulgaris or dermatitis or a wound or injury.

[0048] In the context of the present invention, the term "skin" is understood to mean all or part of the body, in particular the skin of the human body, preferably selected from the leg; foot; underarm; hand; thigh; waist; buttocks; waist; groin; inguinal region; abdomen; nape of the neck; neck; arm; torso; back; forehead, cheek, nose, temple, T-zone (forehead, nose and chin), external auditory canal and / or face including the chin; and / or scalp, more preferably the leg, foot, underarm, hand, thigh, abdomen, nape of the neck, neck, arm, torso, back, face and / or scalp, advantageously the underarm, nape of the neck, face, more advantageously the face.

[0049] In the context of the present invention, the term "mucosa" is understood to mean the nose, eyes, vagina, urogenital tract and / or buccal mucosa, in particular the lip and / or gum mucosa, preferably the urogenital tract and / or cheek, preferably the lip mucosa.

[0050] According to the present invention, the term "body surface growth" is understood to mean hair fibers (head hair), eyelashes, eyebrows, body hair, in particular the beard, and / or mustache hair, and / or nails, preferably nails and head hair.

[0051] In the context of the present invention, the term "lipophilic and fat-dispersible molecule" is understood to mean a molecule that is soluble and dispersible in a liquid oily phase, typically sunflower oil, at ambient temperature (i.e., 18 °C to 25 °C) or after heating at 60 °C to 85 °C at atmospheric pressure.

[0052] In the context of the present invention, the term "linear molecule" is understood to mean an alkane, ester, acid, carbonate or alcohol molecule in which the carbon-based chain contains no branches. Thus, the molecule contains one or two linear carbon-based chains, i.e., saturated or unsaturated carbon-based chains in which each carbon atom is covalently bonded to a maximum of two other carbon atoms. Thus, it does not contain carbon groups branched on the carbon chain.

[0053] In the context of the present invention, the term "branched-chain molecule" is understood to mean a molecule in which the chain contains at least one branch. Thus, the molecule contains at least one branched carbon-based chain, i.e., a saturated or unsaturated carbon-based chain in which at least one carbon atom is covalently bonded to at least three other carbon atoms. It can be saturated or unsaturated and contains at least one carbon group branched on the carbon-based chain.

[0054] In the context of the present invention, the term "linear fat-soluble and fat-dispersible molecule" is understood to mean at least two of the following molecules, preferably selected from the following list, either alone or as a mixture: - An alkane molecule of the chemical formula C n H 2n+2 (where n represents a value in the range of 6 to 40), - An ester molecule of the chemical formula CH3-C x H 2x -C(O)O-C y H 2y -CH3 (where each of the exponents x and y independently represents a value in the range of 5 to 19), - Dicaprylyl carbonate, - An acid molecule of the chemical formula CH3-C x H 2x -C(O)OH (where x represents a value in the range of 5 to 24, preferably 5 to 21), and - An alcohol molecule of the chemical formula CH3-C x H 2x -OH (where x represents a value in the range of 5 to 21).

[0055] In particular, linear fat-soluble and fat-dispersible molecules may be selected from dicaprylyl carbonate; coco-caprylate, optionally in combination with coco-caprate, preferably a mixture of coco-caprylate and coco-caprate; undecane and / or tridecane; linoleic acid and / or oleic acid and / or their linear esters (e.g., isostearyl linoleate) and / or oleyl alcohol; behenyl alcohol and / or its acid and ester derivatives, in particular behenic acid or docosanoic acid ester or behenic acid ester, also denoted as docosanoic acid; and / or mixtures thereof.

[0056] In the context of the present invention, the term "selected linear fat-soluble and fat-dispersible molecules" is understood to mean at least two of the following molecules, preferably selected from the following list, either alone or as a mixture: dicaprylyl carbonate; coco-caprylate, optionally in combination with coco-caprate, preferably a mixture of coco-caprylate and coco-caprate; undecane and / or tridecane; linoleic acid and / or oleic acid and / or their linear esters (e.g., isostearyl linoleate) and / or oleyl alcohol; behenyl alcohol and / or its acid and ester derivatives, in particular behenic acid or docosanoic acid ester or behenic acid ester, also denoted as docosanoic acid; and / or mixtures thereof.

[0057] In the context of the present invention, the term "other linear fat-dispersible and fat-soluble molecules" is understood to mean linear fat-dispersible and fat-soluble molecules as defined above, but different from the selected linear fat-soluble and fat-dispersible molecules as defined above.

[0058] In the context of the present invention, the term "derivative" of an acid molecule is understood to mean alcohol derivatives and ester derivatives.

[0059] In the context of the present invention, the term "derivative" of an alcohol molecule is understood to mean acid and ester derivatives.

[0060] In the context of the present invention, the term "maintaining viability" is understood to mean preventing an increase and / or decrease over time in the number of colony forming units (referred to as CFU) of viable bacterial strains in the composition. The viability of the viable bacterial strains according to the present invention is said to be "maintained" when the number of CFUs counted after a given time varies by at most 2 logarithms, preferably 1 logarithm, although there is a difference, relative to the number of CFUs initially counted during the formulation of the composition according to the present invention.

[0061] Maintenance of viability is preferably evaluated after a period ranging from 1 month to 24 months, preferably after 1 month, preferably after 3 months, more preferably after 6 months, even more preferably after 12 months and / or 16 months and / or 18 months, starting from the formulation of the composition according to the present invention, at a predetermined time.

[0062] Maintenance of viability is preferably evaluated after storage at 0°C to 30°C, more preferably at 2°C to 25°C, more preferably at 2°C to 6°C and / or 10°C to 30°C, preferably at ambient temperature (i.e., 18°C to 25°C, especially approximately 21°C).

[0063] The number of CFUs can be evaluated by taking a predetermined amount of the composition placed in a suitable culture medium, by methods conventional in the art, in particular by counting the bacterial strains, in particular as described in Example 2.

[0064] In the context of the present invention, the term "maintaining stability" of a composition containing viable bacterial strains means preventing an increase or decrease in parameters conventionally defined in the art, such as sensory parameters such as color and / or odor and / or pharmaceutical formulation parameters such as pH, maintenance of the phase, absence of precipitation of compounds and / or absence of growth of another microbial strain.

[0065] The viable bacterial strains used in the present invention are referred to as probiotics. In the context of the present invention, the term "probiotic or probiotic bacterial strain" is understood to mean one or more bacterial strains that are alive and thus viable, i.e., capable of forming colonies during cultivation. The bacterial strains referred to as probiotics according to the present invention are of interest in the fields of cosmetology and / or dermatology and can be administered topically without posing a danger to humans.

[0066] In the context of the present invention, the term "viable probiotic bacterial strain" is understood to mean the entire population of viable bacterial strains, i.e., bacterial strains capable of forming colonies during cultivation.

[0067] In the context of the present invention, the term "physiologically acceptable excipient" is understood to mean an excipient that is suitable for topical application, cosmetic, pharmaceutical or dermatological use, is non-toxic and non-irritating to the skin, does not induce an allergic response and is not chemically unstable.

[0068] The term "topical administration or topically" is understood to mean the direct topical application and / or spraying of the composition onto the surface of the skin, in particular the scalp, and / or the mucous membranes, and / or the cutaneous growths. Thus, the composition can advantageously be selected from the legs; feet; underarms; hands; thighs; waist; buttocks; waist; groin; inguinal region; abdomen; earlobes; neck; arms; torso; back; forehead, cheeks, nose, temples, T-zone (forehead, nose and chin), oral mucosa, external auditory canal and / or chin; hair; and / or scalp, more preferably the legs, feet, underarms, hands, thighs, abdomen, earlobes, neck, arms, torso, back, face, hair, nails and / or oral mucosa and / or scalp, advantageously the earlobes, face, hair, nails and / or oral mucosa, more advantageously the face; underarms, earlobes, hair, nails, oral mucosa, scalp and / or face, very advantageously the face, and can be topically applied to all or part of the body and / or face.

[0069] Due to the complementary skin softening properties of the fat-soluble and fat-dispersible molecules selected according to the present invention, the cosmetic composition according to the present invention is particularly suitable for all types of skin, in particular skin and / or mucous membranes referred to as normal and / or dry and / or sensitive and / or sensitized and / or fragile and / or weakened skin and / or mucous membranes, and / or skin and / or mucous membranes having an atopic tendency, and / or for the cosmetic care and / or treatment of the aesthetically non-pleasing and / or unpleasant symptom manifestations of dry skin and / or mucous membranes.

[0070] Healthy skin and / or healthy mucous membranes are generally defined as "sensitive skin and / or mucous membranes" which are essentially skin and / or healthy mucous membranes with only slight resistance to aggressive factors, in particular contaminants, climatic factors (wind, cold, heat), UV exposure, emotional factors, in particular stress and / or chemicals (heavy metals; detergents; compounds contained in cosmetics such as fragrances, preservatives, alcohol, pH, AHA; or dermatological therapeutics such as retinoic acid) and / or aggressive conditions, in particular sweating; mechanical irritation such as hair removal, shaving, scrubbing; and further environmental factors such as water, in particular hard water. Sensitive skin, unlike allergic skin, is not skin with pathological characteristics. Nevertheless, they can react to aggressive factors and / or conditions by non-aesthetic and / or unpleasant skin and / or mucous membrane symptom manifestations such as dryness of the skin and / or mucous membranes, loss of homogeneity of skin and / or mucous membrane color gloss, in particular the appearance of redness, tightness, stinging, pricking, pulling and / or itching, rough appearance and / or loss of softness of touch of the skin and / or mucous membranes. Therefore, the characteristics of "sensitive skin" can be evaluated by the subjective skin sensations of the subject himself or by the objective skin reactions of a dermatologist.

[0071] Non-aesthetic and / or unpleasant symptom manifestations can sometimes spread systemically, but in most cases they can have clearly defined locations such as the scalp, face, skin folds, buttocks of infants, etc. Therefore, it can be a problem of sensitive skin and / or mucous membrane sites.

[0072] Similarly, "sensitized skin and / or mucosa" refers to healthy skin and / or healthy mucosa that has become temporarily sensitive and is therefore non-pathological.

[0073] "Vulnerable or weakened skin and / or mucosa (i.e., skin or mucosa that has become temporarily vulnerable)" refers to a state in which the barrier function of healthy skin and / or healthy mucosa has been weakened. This state can be related to an individual's condition and / or age, for example, in the elderly or infants with vulnerable skin. This state can also be caused by chemical or physical attacks (abrasion, scrubbing, cuts).

[0074] Similarly, the dermatological composition according to the present invention is particularly suitable for the dermatological care and / or treatment of pathological skin and / or mucosa, in particular atopic and / or reactive skin and / or mucosa.

[0075] "Skin and / or mucosa with an atopic tendency" refers to extremely vulnerable and / or weakened healthy skin and / or healthy mucosa that has increased skin permeability due to a decrease in the barrier function and has a genetic predisposition to change into a pathological state of atopic dermatitis under the influence of multiple endogenous and exogenous factors. Therefore, the characteristics of "skin with an atopic tendency" can be evaluated by the subjective skin sensation of the subject himself or the objective skin reaction by a dermatologist.

[0076] The unpleasant and / or aesthetically non-pleasing symptom manifestations of sensitized, vulnerable and / or weakened skin and / or mucosa are the same as those of sensitive skin and / or mucosa, and these symptom manifestations and / or the state of the skin are not the subject of disease prevention and / or treatment.

[0077] "Reactive skin and / or mucosa" is also known as intolerance or hypersensitivity or allergy, and is skin and / or mucosa that has a reduced tolerance threshold and reacts excessively.

[0078] "Atopic skin and / or mucosa" refers to skin and / or mucosa affected by the pathological condition of atopic dermatitis.

[0079] The characteristics of "reactive skin and / or mucosa" and "atopic skin and / or mucosa" can be evaluated by a dermatologist based on objective skin reactions.

[0080] In connection with the present invention, a cosmetic and / or dermatological composition comprises - at least one live probiotic bacterial strain, and - at least one selected linear fat-dispersible and fat-soluble molecule, and - optionally, one or more other linear fat-dispersible and fat-soluble molecules wherein the total content of the linear fat-dispersible and fat-soluble molecules is at least 40% by weight based on the total weight of the composition.

[0081] The selected linear fat-soluble and fat-dispersible molecules according to the present invention are - dicaprylyl carbonate, - coco-caprylate optionally combined with coco-caprate, preferably a mixture of coco-caprylate and coco-caprate, - undecane and / or tridecane, - linoleic acid and / or oleic acid and / or their linear esters (e.g., isostearyl linoleate) and / or oleyl alcohol, - behenyl alcohol and / or its acid and ester derivatives, in particular behenic acid, also known as docosanoic acid or docosanoic acid ester or behenic acid ester, and / or any one of their mixtures selected from.

[0082] This is because, as demonstrated in Example 2, the applicant has observed that these selected linear molecules enable the viability of the probiotic bacterial strain to be maintained.

[0083] In particular, the selected linear fat-soluble and fat-dispersible molecules according to the present invention are as follows: · Linear acids: - Dicaprylyl carbonate: Also known as dioctyl carbonate, chemical formula C 17 H 34 O3 and CAS number 1680 - 31 - 5; this molecule is a diester of carbonic acid and caprylyl alcohol. It has conventionally been sold by BASF under the name Cetiol® CC or is contained in mixtures such as the Cosmedia® Gel CC product sold by BASF. - Cococaprylate: INCI name coco - caprylate, also known as cocoalkyl octanoate (CAS 107525 - 85 - 9); this ester with a straight - chain fatty chain has conventionally been sold by BASF under the name Cetiol® C5. - Cococaprylate can be combined with cococaprate (INCI name cococaprylate / caprate); this combination with INCI name cococaprylate / caprate and CAS number 95912 - 86 has conventionally been sold by BASF under the name Cetiol® C5C.

[0084] These straight - chain acids are known and are used in cosmetic and / or dermatological compositions as skin softeners.

[0085] · Straight - chain alkanes: - Undecane: This is an alkane with chemical formula C 11 H 24 and CAS number 1120 - 21 - 4, - Tridecane: This alkane with chemical formula C 13 H 28 and CAS number 629 - 50 - 5 has conventionally been sold by BASF under the name Cetiol® iSan, - A mixture of undecane and tridecane has conventionally been sold by BASF under the name Cetiol® Ultimate.

[0086] · Straight - chain fatty acids or their derivatives: - Linoleic acid: This is an omega-6 polyunsaturated fatty acid. It can be included in mixtures rich in linoleic acid, such as argania spinosa seed oil, which is sold, in particular, by the Applicant under the name Lipofructyl (trademark) Argan. Preferably, linoleic acid is added in a form contained in a mixture rich in linoleic acid, i.e., in a form containing at least 70% of linoleic acid, or in a pure form. - Oleic acid: This is an omega-9 monounsaturated fatty acid. It can be contained in mixtures rich in linoleic acid, i.e., containing at least 50%, preferably at least 70% thereof, in the form of, for example, rapeseed oil rich in omega-9, such as that sold by BASF under the name Cegesoft PS6. - A linear ester of linoleic acid or oleic acid is a linear molecule containing a group with a maximum of 20 carbon chains esterified with an acid functional group, such as isostearyl linoleate or decyl oleate. - Oleyl alcohol.

[0087] · Linear fatty alcohol: - Behenyl alcohol: This is also known as docosanol and is represented by the chemical formula C 22 H 46 O and is sold by BASF under the name Lanette (registered trademark) 22. Its acid and ester derivatives are selected, in particular, from behenic acid (also known as docosanoic acid), its docosanoic acid ester or behenic acid ester; and / or mixtures thereof.

[0088] Advantageously, the selected linear fat-soluble and fat-dispersible molecules are contained in cosmetic and / or dermatological compositions in a minimum content of 8% by weight, more preferably at least 10%, preferably at least 15% by weight, preferably 40% by weight, more preferably at least 50% by weight, advantageously at least 60% by weight, more preferably 70% by weight, based on the total weight of the composition.

[0089] The cosmetic and / or dermatological composition according to the invention advantageously comprises a mixture of at least two, preferably three or four, of the selected linear liposoluble and fat-dispersible molecules, provided that the total content of linear liposoluble and fat-dispersible molecules is at least 40% by weight, preferably at least 50% by weight, more preferably at least 60% by weight, relative to the total weight of the cosmetic and / or dermatological composition.

[0090] According to one embodiment, the selected linear liposoluble and fat-dispersible molecules are used as molecules contained in a mixture containing them, such as a purified molecule or an extract. In particular, they are used as purified molecules.

[0091] The selected linear liposoluble and fat-dispersible molecules according to the invention can be combined with other linear fat-dispersible and liposoluble molecules which have not been selected, provided that the total content of linear liposoluble and fat-dispersible molecules is at least 40% by weight, preferably at least 50% by weight, more preferably at least 60% by weight, relative to the total weight of the cosmetic and / or dermatological composition.

[0092] These other linear fat-dispersible and liposoluble molecules which can be contained in the composition in combination with these selected linear liposoluble and fat-dispersible molecules are preferably selected from the following: - an alkane molecule of the formula C n H 2n+2 (wherein n represents a value in the range of 6 to 40), preferably one of paraffins where n is from 8 to 40, advantageously from 20 to 40 or from 8 to 19, such as, for example, dodecane, tetradecane and / or pentadecane, - an ester molecule of the formula CH3-C x H 2x -COO-C y H 2y -CH3 (wherein each of the exponents x and y independently represents a value in the range of 3 to 19), such as, for example, myristyl myristate C 28 H 56 O2, cetearyl palmitate, cetyl palmitate, butyl palmitate or myrsyl palmitate, - Acid molecule with chemical formula CH3-C x H 2x -C(O)OH (where x represents a value in the range of 5 to 24, preferably 5 to 21), such as serotic acid, - Alcohol molecule with chemical formula CH3-C x H 2x -OH (where x represents a value in the range of 5 to 21), and any one of their mixtures.

[0093] According to a preferred embodiment, the present invention relates to a composition intended for topical application, in particular a cosmetic and / or dermatological composition, comprising at least one live probiotic bacterial strain and at least 40% by weight, based on the total weight of the composition, of one or more selected linear liposoluble and fat-dispersible molecules, preferably at least two selected linear liposoluble and fat-dispersible molecules.

[0094] Advantageously, the composition according to the invention does not contain paraffin or glycerin.

[0095] The cosmetic and / or dermatological composition according to the invention advantageously comprises a mixture of at least two, preferably three or four, of the selected linear liposoluble and fat-dispersible molecules, the total of which is at least 40% by weight, preferably 50% by weight, based on the total weight of the cosmetic and / or dermatological composition.

[0096] According to a particular embodiment of the present invention, the linear liposoluble and fat-dispersible molecules comprised in the cosmetic and / or dermatological composition are selected only from the selected linear liposoluble and fat-dispersible molecules. In other words, the cosmetic and / or dermatological composition according to the present invention does not contain linear liposoluble and fat-dispersible molecules other than the selected ones.

[0097] According to a particular embodiment of the present invention, the cosmetic and / or dermatological composition consists of one or more selected linear liposoluble and fat-dispersible molecules and a live probiotic bacterial strain.

[0098] The composition according to the invention contains at least one live probiotic bacterial strain. According to the invention, the term "live probiotic bacterial strain" is understood to mean a bacterial strain that is the subject of interest in cosmetology and / or dermatology, i.e., a non-pathogenic bacterial strain whose local contribution can improve the aesthetics and / or comfort of healthy skin or treat a pathological condition. It can relate to wild-type or genetically modified bacteria.

[0099] Preferably, it relates to the following bacteria: - The lactic acid bacteria group, in particular Lactobacillus rhamnosus, brevis, crispatus, delbrueckii, fermentum, helveticus, plantarum, iners, gasseri, jensenii, reuteri, brevis and / or acidophilus, preferably Lactobacillus crispatus, - The coccus group, in particular Alloicoccus otitis, Lactococcus lactis, Streptococcus thermophilus, Streptococcus salivarius, Staphylococcus epidermidis, Staphylococcus hominis, Staphylococcus warneri, Staphylococcus caprae and / or Staphylococcus saprophyticus, - The Micrococcus group, particularly Micrococcus luteus, - The Bifidobacteria group, particularly Bifidobacterium longum and / or Bifidobacterium infantis, - The Corynebacterium group, particularly Corynebacterium accolens, Corynebacterium tuberculostearicum and / or Corynebacterium amycolatum, - The Sphingomonas group, particularly Sphingomonas glacialis, - The Bacillus group, particularly Bacillus cereus (subtilis) and / or Bacillus licheniformis, and - The Cutibacterium genus, particularly Cutibacterium acnes.

[0100] More preferably, the following bacteria are involved: - Lactobacillus spp., especially Lactobacillus rhamnosus, brevis, crispatus, delbrueckii, fermentum, helveticus, plantarum, iners, gasseri, jensenii, reuteri, brevis and / or acidophilus, preferably Lactobacillus crispatus, - Cocci, especially Alloicoccus otitis, Lactococcus lactis, Streptococcus thermophilus, Streptococcus salivarius, Staphylococcus epidermidis and / or Staphylococcus hominis, - Bifidobacteria, especially Bifidobacterium longum and / or Bifidobacterium infantis, - Corynebacterium spp., especially Corynebacterium accolens, - Sphingomonas spp., especially Sphingomonas glacialis, - Bacillus spp., especially Bacillus cereus (subtilis) and / or Bacillus licheniformis, - Cutibacterium spp., in particular Cutibacterium acnes.

[0101] Preferably, the live probiotic bacterial strain is selected from Lactobacillus crispatus, Corynebacterium accolens, Sphingomonas glacialis, Streptococcus salivarus, and mixtures thereof.

[0102] Particularly preferably, the live probiotic bacterial strain is any of the following strains deposited at the Pasteur Institute (25 rue du Docteur Roux, F-75724 Paris Cedex 15) in accordance with the Budapest Treaty: - Lactobacillus crispatus strain deposited under the number CNCM I-5579, - Sphingomonas glacialis strain deposited under the number CNCM I-5829.

[0103] The live probiotic bacterial strain can be formulated in a powdered state, i.e., in a dry form or in the form of a suspension.

[0104] Generally, the live probiotic bacterial strain can be isolated before being added to the composition, i.e., not mixed with one or more compounds of its original medium. Alternatively, the live probiotic bacterial strain can be combined with its original medium, particularly the compounds of its culture medium.

[0105] According to a preferred embodiment, a live probiotic bacterial strain can be combined with the bacterial strain in an inactivated form, particularly in a killed form and / or in the form of its lysate, and / or in the form of one or more fractions thereof, and / or in the form of one or more metabolites thereof, particularly in the form of its secretome. Thus, it can relate to the same bacterial strain in an inactivated form or to another bacterial strain in an inactivated form. Preferably, it relates to the same bacterial strain as the live probiotic bacterial strain.

[0106] According to one embodiment, the composition of the present invention may contain several live probiotic bacterial strains, or a live probiotic bacterial strain combined with another bacterial strain in an inactivated form, particularly in a killed form and / or in the form of its lysate, and / or in the form of one or more fractions thereof, and / or in the form of one or more metabolites thereof, particularly in the form of its secretome.

[0107] Particularly preferably, the live probiotic bacterial strain is contained in a cosmetic and / or dermatological composition at a concentration of 0.001% to 3% (w / w), more preferably 0.01% to 0.3% (w / w), approximately 0.025% (w / w) based on the total weight of the composition.

[0108] Advantageously, the live probiotic bacterial strain is 10 3 colony forming units (CFU) to 10 15 CFU / g, preferably 10 4 to 10 10 CFU / g, more preferably 10 5 to 10 9 CFU / g, more preferably 10 5 to 10 8 CFU / g, more preferably approximately 10 5 CFU / g and is contained in a cosmetic and / or dermatological composition at this concentration.

[0109] Advantageously, the live probiotic bacterial strain is 10 3~10 8 in the range of CFU / g, more preferably 10 4 ~10 8 in the range of CFU / g, more preferably 10 5 ~10 8 more preferably in the range of approximately 10 CFU / g 5 is contained in the cosmetic composition at a concentration of CFU / g.

[0110] Advantageously, the live probiotic bacterial strain is 10 per gram of the composition 9 colony forming units (CFU) to 10 15 in the range of CFU / g, preferably 10 9 ~10 13 is contained in the dermatological composition at a concentration in the range of CFU / g.

[0111] The production of the live probiotic bacterial strain can be carried out according to any method conventionally known to those skilled in the art. Advantageously, for example, it is carried out according to the protocol described in Example 1.

[0112] According to an advantageous embodiment, the cosmetic and / or dermatological composition according to the invention has a water activity of less than 0.6, more preferably less than 0.5, even more preferably less than 0.4.

[0113] Water activity (AW) indicates the availability of the so-called "free" water in the matrix. Thus, it is not the exact amount of water in the medium, but only the amount of water that can participate in chemical, biochemical, and microbiological reactions. This is defined relative to pure water, and thus the reference state without solutes. The value of AW varies from 0 to 1. If the product is dry and all water is bound to the matrix (non-reactive), it is equal to 0. In the case of pure water, it is equal to 1.

[0114] Water activity is measured in a manner conventionally recognized by those skilled in the art using a water activity measuring device such as an Aqualab device sold by Metergroup, for example.

[0115] According to a more preferred embodiment, the composition according to the invention contains at most 5% by weight, preferably less than 3% and more preferably no added water, based on the total weight of the composition. According to a particular embodiment, the composition according to the invention is a non-aqueous composition.

[0116] According to a particular embodiment of the invention, the live probiotic bacterial strain is included in the oil phase (or non-aqueous phase). As an alternative, the live probiotic bacterial strain of the invention can be used dispersed and / or diluted in a solvent. Preferably, this solvent contains less than 20% by volume (v / v) of water, more preferably less than 5% by volume (v / v) of water; more preferably the solvent contains no water.

[0117] According to a preferred embodiment, this solvent contains less than 20% by weight (w / w) of water, more preferably less than 5% by weight (w / w) of water; more preferably the solvent contains no water. Most preferably, this solvent is one of the fat-soluble and fat-dispersible molecules selected according to the invention.

[0118] The live probiotic bacterial strain according to the invention is preferably added to the composition according to the invention in a strain content of preferably 10% to 80% by weight (w / w), more preferably 30% to 70% by weight (w / w), even more preferably 40% to 60% by weight (w / w), based on the total weight of the powder, preferably in dry form, i.e. in powder form, preferably in maltodextrin.

[0119] According to a particular embodiment, the cosmetic and / or dermatological composition of the invention, in its implementation, - At least one live probiotic bacterial strain selected from Lactobacillus crispatus, Corynebacterium accolens, Sphingomonas glacialis, Streptococcus salivarus and mixtures thereof, preferably the Lactobacillus crispatus strain deposited under number CNCM I-5579 and preferably the Sphingomonas glacialis strain deposited under number CNCM I-5829, - Dicaprylyl carbonate; coco caprylate optionally combined with coco caprate, preferably a mixture of coco caprylate and coco caprate; undecane and / or tridecane; linoleic acid and / or oleic acid and / or their linear esters (e.g., isostearyl linoleate) and / or oleyl alcohol; behenyl alcohol and / or its acid and ester derivatives, in particular behenic acid also denoted as docosanoic acid or docosanoic acid ester or behenic acid ester; and at least one linear lipophilic and fat-dispersible molecule selected from any of their mixtures, - At least one other linear lipophilic and fat-dispersible molecule, and - A total content of linear lipophilic and fat-dispersible molecules of at least 40% by weight, preferably 50% by weight, based on the total weight of the composition may comprise, - The live probiotic bacterial strain is preferably ○10 4 ~10 10 CFU / g, more preferably 10 5 ~10 9 CFU / g, more preferably 10 5 ~10 8 CFU / g in the range of content, ○ In the form of a lyophilized powder on a maltodextrin support, it is added to the composition in a strain content range of 40% to 60% by weight based on the total weight of the maltodextrin powder.

[0120] In a preferred embodiment, the cosmetic and / or dermatological composition according to the invention - At least one live probiotic bacterial strain selected from Lactobacillus crispatus, Corynebacterium accolens, Sphingomonas glacialis, Streptococcus salivarus and mixtures thereof, preferably the Lactobacillus crispatus strain deposited under the number CNCM I-5579 and preferably the Sphingomonas glacialis strain deposited under the number CNCM I-5829 - Dicaprylyl carbonate; coco caprylate optionally combined with coco caprate, preferably a mixture of coco caprylate and coco caprate; undecane and / or tridecane; linoleic acid and / or oleic acid and / or their linear esters (e.g., isostearyl linoleate) and / or oleyl alcohol; behenyl alcohol and / or its acid and ester derivatives, in particular behenic acid also denoted as docosanoic acid or docosanoic acid ester or behenic acid ester; and at least one, preferably at least two, linear lipophilic and fat-dispersible molecules selected from any of their mixtures - A total content of at least 40% by weight, preferably 50% by weight, of the selected linear lipophilic and fat-dispersible molecules based on the total weight of the composition and - The live probiotic bacterial strain is preferably ○ 10 4 ~ 10 10 CFU / g, more preferably 105 ~10 9 CFU / g, more preferably 10 5 ~10 8 is in the content range of CFU / g, ○ In the form of a lyophilized powder on a maltodextrin support, it is added to the composition in a strain content range of 40% to 60% by weight based on the total weight of the maltodextrin powder.

[0121] The beauty and / or dermatological composition is manufactured according to conventional compounding methods.

[0122] Preferably, the live probiotic bacterial strain is preferably directly dispersed in a linear and / or branched-chain lipid-soluble and fat-dispersible molecule, preferably a linear one, more preferably a selected linear one, namely dicaprylyl carbonate; capric / caprylic triglyceride optionally combined with coco-caprylate, preferably a mixture of capric / caprylic triglyceride and coco-caprylate; undecane and / or tridecane; linoleic acid and / or oleic acid and / or their linear esters (e.g., isostearyl linoleate) and / or oleyl alcohol; behenyl alcohol and / or its acid and ester derivatives, particularly behenic acid also denoted as docosanoic acid or docosanoic acid ester or behenic acid ester; and any one of their mixtures.

[0123] Preferably, the composition according to the present invention is manufactured at a maximum temperature of 70 °C in relation to "high temperature" manufacturing or at ambient temperature, i.e., 18 °C to 25 °C, particularly approximately 21 °C, in relation to "low temperature" manufacturing.

[0124] Advantageously, the manufacturing temperature does not exceed 70 °C for a duration of up to 3 hours. This is adjusted according to the tolerance of its live bacterial strain.

[0125] In a preferred embodiment, the composition according to the present invention is manufactured at ambient temperature, i.e., 18 °C to 25 °C, particularly 21 °C, in relation to "low temperature" manufacturing.

[0126] The cosmetic and / or dermatological composition according to the invention is a composition for topical administration.

[0127] In an advantageous embodiment, the composition according to the invention further comprises a physiologically acceptable excipient, in particular a cosmetic, pharmaceutical or dermatologically acceptable excipient.

[0128] In connection with the present invention, live probiotic bacterial strains are used as active agents, in particular cosmetic or dermatological active ingredients, in the composition for preventing and / or reducing the appearance of aesthetically non-pleasing and / or unpleasant symptoms of healthy skin and / or healthy mucous membranes, which are referred to as normal, sensitive, and / or sensitized, and / or fragile, and / or weakened, and / or dried, and / or having an atopic tendency.

[0129] The cosmetic and / or dermatological composition according to the invention can be used in the form of a cosmetic or dermatological agent or in the form of a premix intended to be incorporated into another cosmetic and / or dermatological composition, in particular immediately before its direct application, in a form further comprising a suitable cosmetic excipient or pharmaceutical excipient.

[0130] In this case, according to a particularly advantageous embodiment for this mode of administration, the live probiotic bacterial strain is then, in a more concentrated dose, in particular at a concentration in the range of 0.001% to 3% by weight, more preferably at a concentration of 0.01% to 0.3% by weight, preferably at a concentration of 0.1% to 0.25% by weight, more preferably at a concentration of approximately 0.20% by weight, based on the total weight of the composition, contained in the composition according to the invention.

[0131] Preferably, the composition according to the invention is a cosmetic and / or dermatological composition that can be used immediately, i.e., a composition that can be directly used by topical application.

[0132] The composition according to the invention does not contain biocidal doses of agents and / or preservatives that can have an adverse effect on the viability of live probiotic bacterial strains.

[0133] The composition according to the invention may contain any suitable solvent, excipient or vehicle and other active ingredients, provided that they do not adversely affect the stability of the composition, in particular the viability of live probiotic bacterial strains.

[0134] Advantageously, the composition according to the invention may also contain non-linear liposoluble and fat-dispersible molecules, in particular branched-chain fatty substances, provided that linear liposoluble and fat-dispersible molecules, in particular the selected molecules, are present in the cosmetic composition in a content of at least 40%, preferably at least 50% by weight, more advantageously at least 60% by weight, even more preferably at least 70% by weight, based on the total weight of the composition.

[0135] The term "branched-chain fatty substances" is generally understood to mean liquid, pasty or solid oily compounds having a branched chain, in particular waxes, in particular saturated fatty acids having one or more hydrocarbon-based branches on a vegetable oil and carbon-based chain (conventionally denoted BCFA (branched-chain fatty acids)). These branched-chain fatty substances are generally used in a very large number of cosmetic and / or dermatological compositions as texture agents, emollients, structuring agents or rheology modifiers.

[0136] The branched-chain fatty substances are advantageously selected from oils of the fatty substance type having a branched chain such as, for example, the following: - Octyldodecanol, also known as Eutanol® G; - Propylheptyl caprylate, in particular sold by BASF under the name Cetiol® Sensoft; - A mixture of caprylic triglyceride and capric triglyceride, known under the CAS number 73398-61-5 and sold by BASF under the name Myritol® 318; - Hydrogenated castor oil; - Shea butter or other fatty acids, for example a mixture containing oleic acid, stearic acid, linolenic acid, palmitic acid, linoleic acid and arachidonic acid, sold by BASF under the name Cetiol® SB 45. - Coconut oil and / or coco glycerides, especially sold under the name Myritol® 331 by BASF; - Squalane derivatives such as squalane or hemisqualane.

[0137] Preferably, the composition according to the invention contains a maximum amount of branched-chain fatty substances of 40% by weight, preferably 30% by weight, more preferably less than 20% by weight, based on the total weight of the composition, especially those listed above. This is because, according to this preferred embodiment, as demonstrated in Example 6, the composition exhibits improved viability at ambient temperature.

[0138] According to a particular embodiment of the invention, the cosmetic and / or dermatological composition does not contain non-linear liposoluble and fat-dispersible molecules and thus does not contain branched-chain fatty substances either.

[0139] The composition according to the invention may also contain other liposoluble components such as, for example: - Vitamins or antioxidants that prevent the oxidation of fatty substances, especially vitamin E, also known as tocopherol; - Sensory agents such as microcrystalline cellulose; - Texturizing agents, for example fat phase thickeners and / or gelling agents, such as stearalkonium hectorite and propylene carbonate, especially sold in the form of the Cosmedia® Gel CC mixture sold by BASF in combination with dicaprylyl carbonate; - Other skin softeners.

[0140] Thus, the excipients can be selected from surfactants and / or emulsifiers, buffers, chelating agents, denaturing agents, opacifying agents, pH regulators, reducing agents, stabilizers, thickeners, gelling agents, film-forming polymers, fillers, matting agents, brightening agents, pigments, dyes, fragrances and mixtures thereof. The CTFA (Cosmetic Ingredients Handbook, 2016 edition) describes various cosmetic excipients suitable for use in the present invention.

[0141] Advantageously, the excipient is selected from the group consisting of polyglycerol, esters, cellulose polymers and derivatives, lanolin derivatives, phospholipids, lactoferrin, lactoperoxidase, sucrose-based stabilizers, vitamin E and its derivatives, xanthan gum, natural and synthetic waxes, vegetable oils, triglycerides, unsaponifiable substances, plant sterols, silicones, protein hydrolysates, betaine, amine oxide, plant extracts, sucrose esters, titanium dioxide, glycine, polyglycerol, more preferably steareth-2, steareth-21, glycol-15 stearyl ether, cetearyl alcohol, butylene glycol, caprylyl glycol, natural tocopherol, glycerin, sodium dihydroxycetyl phosphate, isopropyl hydroxycetyl ether, glycol stearate, triisononanoin, octyl cocoate, polyacrylamide, isoparaffin, laureth-7, carbomer, propylene glycol, hexylene glycol, glycerol, bisabolol, dimethicone, sodium hydroxide, PEG-30 dipolyhydroxystearate, caprin / caprylic triglyceride, cetearyl octanoate, dibutyl adipate, grape seed oil, jojoba oil, magnesium sulfate, EDTA, cyclomethicone, xanthan gum, citric acid, sodium lauryl sulfate, mineral oil and wax, isostearyl isostearate, propylene glycol diperargonate, propylene glycol isostearate, PEG8, beeswax, hydrogenated palm kernel oil glyceride, lanolin oil, sesame oil, cetyl lactate, lanolin alcohol, castor oil, titanium dioxide, lactose, sucrose and mixtures thereof.

[0142] According to a particularly advantageous embodiment, the composition according to the invention - Advantageously, a locally acceptable alginic acid, its salts and its esterified derivatives, selected from ammonium alginate, sodium alginate, calcium alginate, magnesium alginate, sodium alginate sulfate and potassium alginate, glyceryl alginate or propylene glycol alginate or mixtures thereof, preferably sodium alginate and / or propylene glycol alginate - A locally acceptable hyaluronic acid, its salts and its esterified derivatives, preferably sodium hyaluronate, selected from calcium hydrolyzed hyaluronate, sodium hydrolyzed hyaluronate, potassium hyaluronate, sodium hyaluronate or sodium hyaluronic acid sulfate, - Scleroglucan, and / or Any one of their mixtures Also included is a biodegradable polymer selected from.

[0143] According to a preferred embodiment of the present invention, such polymers are present in the composition according to the present invention, particularly when present in a content of 0.1% to 10% by weight, more preferably 1% to 5% by weight, based on the total weight of the cosmetic and / or dermatological composition. It has been found that the viability of live probiotic bacterial strains is further enhanced.

[0144] The cosmetic and / or dermatological composition according to the present invention can be selected from oily suspensions or solutions, oily creams or gels, emulsions, water-in-oil, or multiple, or silicone-type emulsions, masks, lotions, lotions, solid soaps, solid shampoos, solid foaming products, dermatological bars, ointments, mousses, patches, such as makeup powders, rods or sticks, preferably liquid, pasty or solid anhydrous products.

[0145] Advantageously, the cosmetic and / or dermatological composition according to the present invention is not in the form of a water-in-oil emulsion.

[0146] The cosmetic and / or dermatological composition may further comprise a cosmetic or dermatologically acceptable excipient selected from surfactants, buffers, swelling agents, chelating agents, denaturing agents, emulsifiers, opacifying agents, pH adjusters, reducing agents, stabilizers, emulsifiers, thickening agents, gelling agents, film-forming polymers, solvents, fillers, odor absorbers, matting agents, conditioning agents, texture imparting agents, brighteners, pigments, dyes, fragrances, chemical or inorganic sunscreens, trace elements and essential oils. These combinations are also encompassed by the present invention.

[0147] Cosmetic and / or dermatological compositions may contain other fat-soluble and fat-dispersible active ingredients.

[0148] Cosmetic and / or dermatological compositions are active with respect to the treatment of normal skin and / or mucous membranes, sensitive, sensitized, reactive, fragile and / or weakened skin and / or mucous membranes, and / or are effective for the increase and / or protection and / or maintenance of the beneficial indigenous flora of the skin and / or mucous membranes, and may further contain other components selected, for example, from the following, which induce a complementary or synergistic effect with the probiotic bacterial strains according to the invention: - A combination of sodium hyaluronate, pullulan and sodium alginate, in particular sold under the name PatcH2O (trademark) as a formulation containing serine, trehalose, urea and glycerin, or a combination of hyaluronic acid, pullulan and propylene glycol alginate with lactic acid, succinic acid and / or sucrose, - Other cosmetic ingredients intended for the care of sensitive skin, such as plant extracts of Cestrum latifolium as described in the pamphlet of International Publication No. WO 2009 / 112590, sold by the applicant under the name Symbiocell (trademark), butter extracted from the fruit of Irvingia gabonensis, sold by the applicant under the name Irwinol (trademark), extract of the root of Eperua falcata, sold by the applicant under the name Eperuline (trademark), peptide N-acetyl-L-tyrosyl-L-prolyl-L-phenylalanyl-L-phenylalanine amide (INCI: acetyltetrapeptide-15), sold by the applicant under the name Skinasensyl (trademark).

[0149] The cosmetic composition can be active with respect to the microbiota of the skin and / or mucous membranes and / or active with respect to the skin barrier function, and can in particular contain one or more components, especially moisturizing and / or soothing active ingredients, notably the following: oligosaccharides obtained by enzymatic synthesis and sold under the name BioEcolia (trademark) by Solabia, or a complex of α-gluco-oligosaccharides sold under the name Ecoskin (trademark) by the same company, an extract of Alisma plantago-aquatica, an extract of Argania spinosa (Lipofructyl (trademark) Argan), a mixture of ceramides (Sphingoceryl (trademark) VEG), a refined extract of Bordeaux (Betapool (trademark)), a product based on inulin or fructo-oligosaccharides, an extract of Bifidobacterium or an extract of Orthosiphon stamineus (MAT-XS (trademark) Bright) for oily skin care, a natural extract of honey sold under the name Melhydran (trademark) by the applicant, a flax extract sold under the name Oligolin (trademark) by the applicant, an extract of Cassia angustifolia seeds sold under the name Hyalurosmooth (registered trademark) by the applicant, a yeast extract modified by biotechnology sold under the name Relipidium (trademark) by the applicant, Hydagen GG, an extract of Pueraria lobata roots sold under the name Inhipase (trademark) by the applicant, a β-glucan derivative from baker's yeast sold under the name CM-Glucan Forte (trademark) by Mibelle and / or an extract of Mirabilis jalapa sold under the name Pacifeel (trademark) by Sederma, inulin, in particular N-methylglycine as a skin prebiotic sold under the name Scalposine (trademark) by the applicant, an extract of Brassica sold under the name Phytosoothe (trademark) by the applicantA barrier function repair agent extracted from plant sterols in the seeds of Brassica campestris, a moisturizing and soothing agent containing β-glucan sold by the applicant under the name Hydrasensyl Glucan (trademark), a moisturizing agent containing hyaluronic acid and konjac polysaccharides sold under the name Ultra Filling Spheres (trademark), an antioxidant, anti-inflammatory agent, anti-redness agent, and a soothing agent that protects against the effects of pollution, containing an extract of Inonotus obliquus, sold by the applicant under the name Inolixir (trademark), especially an extract of Moringa oleifera seeds sold by the applicant under the name Purisoft (trademark), an extract of Cassia angustifolia sold by the applicant under the name Hyalurosmooth (registered trademark), and a lactic acid bacteria-fermented soybean extract sold by the applicant under the name Phytofim (trademark) Biotic.

[0150] According to a particularly advantageous embodiment, the active ingredients contained in the composition are, for example, an oily extract of Cyperus esculentus sold by the applicant under the name Lipofructyl (registered trademark) Cyperus, an extract of the fruit of Argania spinosa sold by the applicant under the name Argassential (trademark), an extract of the fruit of Schisandra chinensis, and dehydrated oily spheres of hyaluronic acid sold under the name Hyaluronic Filling Spheres, which are oily and / or fat-dispersible.

[0151] Particularly advantageously, the cosmetic and / or dermatological composition according to the invention also contains an extract of the fermentation medium of a probiotic bacterial strain.

[0152] Another subject of the present invention is dicaprylyl carbonate; coco caprylate, optionally combined with coco caprate, preferably a mixture of coco caprylate and coco caprate; undecane and / or tridecane; linoleic acid and / or oleic acid and / or their linear esters (e.g., isostearyl linoleate) and / or oleyl alcohol; behenyl alcohol and / or its acid and ester derivatives, in particular behenic acid, also known as docosanoic acid or docosanoic acid ester or behenic acid ester; or the use of at least one linear lipophilic and fat-dispersible molecule selected from any one of them, said molecule or its mixture being present in a content of at least 40% by weight based on the total weight of the composition, for maintaining the viability of live probiotic bacterial strains in a cosmetic and / or dermatological composition according to the present invention.

[0153] This use is particularly interesting and advantageous in the presence of a cosmetic or dermatological excipient, especially when the composition contains one or more branched-chain fatty substances, especially those defined above, especially when these exceed 10% by weight, preferably exceed 20% by weight, preferably have a content of 20% to 40% by weight based on the total weight of the composition.

[0154] The present invention also relates to the topical non-therapeutic cosmetic use of a cosmetic composition according to the present invention for the cosmetic treatment of normal healthy skin and / or healthy body surface growths and / or healthy mucous membranes, sensitive healthy skin and / or healthy body surface growths and / or healthy mucous membranes, sensitized healthy skin and / or healthy body surface growths and / or healthy mucous membranes, fragile healthy skin and / or healthy body surface growths and / or healthy mucous membranes, weakened healthy skin and / or healthy body surface growths and / or healthy mucous membranes, dry healthy skin and / or body surface growths and / or mucous membranes and / or healthy skin and / or healthy mucous membranes having an atopic tendency.

[0155] The present invention further relates to a beauty care method, which comprises topically applying a beauty composition according to the present invention to at least one site of healthy skin and / or healthy mucous membranes for the beauty treatment of normal healthy skin and / or healthy body surface growths and / or healthy mucous membranes, sensitive healthy skin and / or healthy body surface growths and / or healthy mucous membranes, sensitized healthy skin and / or healthy body surface growths and / or healthy mucous membranes, fragile and / or weakened healthy skin and / or healthy body surface growths and / or healthy mucous membranes, dry healthy skin and / or healthy body surface growths and / or healthy mucous membranes, and healthy skin and / or healthy mucous membranes having an atopic tendency.

[0156] In an advantageous embodiment of the invention, the beauty care method comprises topically applying the beauty composition according to the invention, preferably to the legs; feet; underarms; hands; thighs; waist; buttocks; waist; groin; inguinal region; abdomen; cuffs; neck; arms; torso; back; forehead, cheeks, nose, temples, T-zone (forehead, nose and chin), oral mucosa, ear canal and / or chin, more preferably to the legs, feet, underarms, hands, thighs, abdomen, cuffs, neck, arms, torso, back, face, hair, and / or scalp, preferably selected from the cuffs, face, hair, nails and / or oral mucosa and / or scalp, more preferably the face; underarms, cuffs, hair, nails, oral mucosa, scalp and / or face, very preferably particularly the face, to the whole or a part of the body and / or face.

[0157] In one embodiment, the amount of the live probiotic bacterial strain contained in the beauty composition does not provide a therapeutic effect.

[0158] Advantageously, another subject of the present invention is a cosmetic (non-therapeutic) treatment method for preventing / reducing the appearance of aesthetically non-pleasing and / or unpleasant symptoms of healthy skin and / or healthy body surface growths and / or healthy mucous membranes of an individual in need / wishing for it, which comprises the following stages: a) Identifying, for an individual, the aesthetically non - desirable and / or unpleasant symptom manifestations and / or the sensitivity and / or vulnerability and / or dryness and / or atopy tendency that are desired to be prevented and / or reduced at a site of healthy skin, and / or mucous membrane, and / or body surface growth, and b) Topically applying, to this site of healthy skin and / or healthy body surface growth and / or healthy mucous membrane, a cosmetic composition according to the invention, in an amount effective to prevent and / or reduce the aesthetically non - desirable and / or unpleasant symptom manifestations at this site of the skin, body surface growth and / or mucous membrane and / or in an amount effective to prevent and / or reduce its sensitivity and / or its vulnerability and / or its dryness and / or its atopy tendency.

[0159] The invention further relates to a dermatological composition as defined above, comprising a cosmetically and / or dermatologically acceptable excipient.

[0160] Cosmetically and / or dermatologically acceptable excipients can be selected from surfactants and / or emulsifiers, buffers, chelating agents, denaturing agents, opacifying agents, pH adjusters, reducing agents, stabilizers, thickeners, gelling agents, film - forming polymers, fillers, matting agents, brighteners, pigments, dyes, fragrances and mixtures thereof. The CTFA (Cosmetic Ingredient Handbook, 2016 edition) describes various cosmetic excipients suitable for use in the present invention. A person skilled in the art knows how to adapt the formulation of the composition according to the invention using their general knowledge.

[0161] The present invention further relates to the dermatological composition according to the invention as defined above for use as an anti-inflammatory or antibacterial agent and / or for the treatment and / or prevention of infections of the skin and / or mucous membranes and / or cutaneous growths caused by pathogenic yeasts or bacteria, such as pathogenic microorganisms such as S. aureus, for example fungal infections, eczema, seborrheic or atopic dermatitis, acne and inflammation and / or erythema of the skin or mucous membranes caused by pathogenic yeasts or bacteria, such as pathogenic microorganisms such as S. aureus, in particular for the treatment and / or prevention of nappy rash in infants and / or for the prevention and / or pharmaceutical treatment, in particular dermatological treatment, of conditions associated with reactive and / or atopic skin and / or mucous membranes.

[0162] Another subject of the present invention is a method of treating and / or preventing infections of the skin and / or mucous membranes and / or cutaneous growths induced by pathogenic yeasts or bacteria, such as pathogenic microorganisms such as S. aureus, for example fungal infections, eczema, seborrheic or atopic dermatitis, acne and inflammation and / or erythema of the skin or mucous membranes caused by pathogenic yeasts or bacteria, such as pathogenic microorganisms such as S. aureus, in a patient in need thereof, the method comprising administering to the patient a pharmaceutically or dermatologically effective amount of the composition for the skin according to the invention, and / or for preventing and / or pharmaceutically treating conditions associated with reactive and / or atopic skin, in particular dermatologically treating.

[0163] Another subject of the present invention is an infectious disease of the skin, and / or mucous membrane, and / or body surface growths caused by pathogenic yeasts or bacteria, such as pathogenic microorganisms such as S. aureus, such as mycosis, eczema, seborrheic or atopic dermatitis, acne and skin or mucous membrane inflammation and / or erythema caused by pathogenic yeasts or bacteria, such as pathogenic microorganisms such as S. aureus, in particular for the treatment and / or prevention of diaper rash in infants and / or for preventing and / or pharmaceutically treating conditions associated with reactive and / or atopic skin and / or mucous membranes, in particular for dermatologically treating, the use of the dermatological composition according to the invention for preparing an anti-inflammatory composition and / or an antibacterial composition and / or a pharmaceutical product.

[0164] In an advantageous embodiment, the live probiotic bacterial strain is 10 9 colony forming units (CFU) to 10 15 CFU / g, preferably 10 9 to 10 13 contained in the dermatological composition at a concentration in the range of CFU / g.

[0165] Hereinafter, the present invention will be described using examples. Other objects, features and advantages of the present invention will become apparent to those skilled in the art upon reading the description with reference to the examples. These are shown by way of example and are in no way intended to limit the present invention.

[0166] The examples form an essential part of the present invention, and features that may appear novel with respect to any state of the prior art from the description taken as a whole including the examples form an essential part of the present invention in terms of its function and general nature.

[0167] Therefore, each example has a general scope.

[0168] Furthermore, in the examples, unless otherwise indicated, the temperature is expressed in degrees Celsius and the pressure is atmospheric pressure.

Examples

[0169] Example 1: Preparation of the composition according to the invention The isolated Lactobacillus crispatus bacteria (CNCMI - 5579) were inoculated into an MRS - type medium (Man, Rogosa, Sharpe agar medium) and cultured anaerobically at 37°C. The pH was maintained at pH = 6 and the medium was cultured for 24 hours. At the end of the culture, the entire medium containing the bacteria was centrifuged to recover the cell concentrate, which was freeze - dried in the presence of maltodextrin such that the final amount of maltodextrin was 50% by weight (w / w) with respect to the total weight of the mixture.

[0170] The resulting powder is composed of a mixture of 50% by weight of the L. crispatus strain and 50% by weight of maltodextrin and is dispersed at 0.425% by weight in a sufficient amount of coco - caprylate (Cetiol® C5 sold by BASF) to reach 100% by weight of the composition.

[0171] Example 2: Monitoring the viability of live probiotic bacteria in the composition according to the invention Protocol: The composition according to the invention was obtained according to Example 1.

[0172] The compositions tested were stored at 4°C (T4°C) and at ambient temperature (Tambient, i.e., 18°C - 25°C, particularly approximately 21°C). At the start of the test (T0) and at regular intervals (T1 month, T2 months, T3 months, T6 months, T12 months, T16 months), the composition was sampled and spread on MRS (Man Sharpe Rugosa) agar medium. The agar medium was cultured in an anaerobic jar at 37°C for 3 days and then the colonies were counted. The results are shown in Table 1 in CFU (colony - forming units) per gram of composition ([Table 1]).

[0173] Results:

[0174] [Table 1]

[0175] The compositions tested according to the present invention show good maintenance of the viability of live bacterial strains due to the presence of sufficient amounts of linear lipophilic and fat-dispersible molecules.

[0176] Example 3: Comparative test by addition of two linear molecules according to the invention Protocol: Composition 1 is produced from the same initial mixture in powder form consisting of 50 wt% of L. crispatus strain and 50 wt% of maltodextrin, and this composition is dispersed at 1% (w / w) in a branched-chain ester (capric acid / caprylyl triglyceride in this example) in an amount sufficient to make the composition 100% (w / w).

[0177] Subsequent Composition 2 is produced from the same initial mixture in powder form consisting of 50 wt% of L. crispatus strain and 50 wt% of maltodextrin: Phase A: % (w / w) with respect to the final composition - Caprylic / capric triglyceride 39.08 - Cococaprylate / caprate mixture 20 - Vegetable oil 20 - Linoleic acid 20 - Tocopherol 0.5 Phase B: - L. crispatus / maltodextrin mixture (1:1 ratio) 0.42

[0178] The components of Phase A are mixed at ambient temperature, and then Phase B is added with gentle stirring. Composition 2 contains 40% of linear lipophilic and fat-dispersible molecules according to the invention.

[0179] The viability of the probiotic bacterial strain is monitored in the same manner as in Example 2 (see [Table 2]).

[0180] Results:

[0181]

Table 2

[0182] After storing Composition 1 containing capric / caprylic triglyceride at 4°C for 1 day, no viable bacteria were measured anymore. By adding the linear fat-soluble and fat-dispersible molecules according to the present invention in an amount of 40% by weight based on the total weight of the composition, it becomes possible to recognize the viability of viable probiotic bacterial strains.

[0183] Example 4: Comparative test by adding three linear molecules according to the present invention Composition 3 is produced from the same initial powder mixture containing 50% by weight of L. crispatus strain and 50% by weight of maltodextrin, and this composition is dispersed in a fatty substance (in this example octyldodecanol) consisting of an alcohol-type branched fatty chain at 1% (w / w) in an amount sufficient to make the composition 100% (w / w).

[0184] Subsequent Composition 4 is produced from the same initial powder mixture consisting of 50% by weight of L. crispatus strain and 50% by weight of maltodextrin: Phase A: % (w / w) with respect to the final composition - Dicaprylyl carbonate 11.95 - Vegetable oil 10 - Cococaprylate / caprate mixture (Cetiol C5C) 25 - Caprylic / capric triglyceride 20 - Octyldodecanol 25 - Tocopherol 0.5 - Mixture of undecane and tridecane (Cetiol® Ultimate) 5.00 - Argania spinosa kernel vegetable oil (active ingredient) 2.50 Phase B: - L. crispatus / maltodextrin mixture (1:1 ratio) 0.05

[0185] The components of phase A are mixed at ambient temperature, and then phase B is added with gentle stirring. Composition 4 contains 42% (w / w) of linear lipophilic and fat-dispersible molecules (dicaprylyl carbonate, coco-caprylate / caprate, and a mixture of undecane and tridecane) according to the present invention.

[0186] The viability of the probiotic bacterial strain is monitored in the same manner as in Example 2 (see [Table 3]).

[0187] Results:

[0188]

Table 3

[0189] After storing Composition 3 containing octyldodecanol at 4°C for 2 months, no viable bacteria are measured. By adding linear lipophilic and fat-dispersible molecules according to the present invention in an amount of 42% by weight based on the total weight of the composition, it becomes possible to maintain the viability of the probiotic bacterial strain.

[0190] Example 5: Comparative test by adding four linear molecules according to the present invention The following Composition 5 is produced from the same initial mixture in powder form consisting of 50% by weight of L. crispatus strain and 50% by weight of maltodextrin: Phase A: % (w / w) relative to the final composition - Dicaprylyl carbonate 13 - Coco-caprylate / caprate mixture (Cetiol C5C) 13 - Shea butter 4 - Cocoglycerides 12 - Octyldodecanol 13.65 - Hydrogenated castor oil 4 - Behenyl alcohol 8 - Tocopherol 0.5 - Microcrystalline cellulose 20 Phase B: - Mixture of undecane and tridecane (Cetiol® Ultimate) 10.00 - Mixture of L. crispatus / maltodextrin (1:1 ratio) 0.05

[0191] Heat at 85 °C with stirring to mix the components of Phase A. Once Phase A is homogeneous, add Phase B with gentle stirring at 65 °C, then cool the mixture to ambient temperature. Composition 5 contains 44% (w / w) of linear lipophilic and fat-dispersible molecules (dicaprylyl carbonate, coco-caprylate / capric acid ester, mixture of undecane and tridecane, and behenyl alcohol) according to the present invention.

[0192] The viability of the probiotic bacterial strain is monitored in the same way as in Example 2 (see [Table 4]).

[0193] Results:

[0194] [Table 4]

[0195] After storing Composition 3 containing octyldodecanol at 4 °C for 2 months, no viable bacteria are measured. By adding linear lipophilic and fat-dispersible molecules according to the present invention in an amount of 44% by weight based on the total weight of the composition, it becomes possible to maintain the viability of the probiotic bacterial strain.

[0196] Example 6: Comparative test containing at least 40% of linear molecules according to the present invention a) Incorporation into the branched-chain molecule squalane. The composition is produced from the same initial mixture in powder form containing 50% by weight of L. crispatus strain and 50% by weight of maltodextrin, to which 1% by weight of squalane is added based on the total weight of the composition (the ratio of squalane + L. crispatus / maltodextrin mixture is 1:1).

[0197] Squalane has the chemical formula C 30 H 62 and is a branched-chain molecule.

[0198] The viability of the probiotic bacterial strain is monitored in the same manner as in Example 2 at 4°C (see [Table 5]).

[0199] Results:

[0200]

Table 5

[0201] After 2 months of storage, the viability of the live bacterial strain decreased by more than 2 logarithmic units, and after 3 months, no live bacteria were measured in the composition. From these results, it can be predicted that the viability of live bacteria at ambient temperature is lost at least as rapidly, and actually more rapidly.

[0202] b) A formulation in which at least 30% of the linear molecules according to the invention are present The following Composition 6 is produced from the same initial mixture in powder form consisting of 50% by weight of L. crispatus strain and 50% by weight of maltodextrin: Phase A: % (w / w) with respect to the final composition - Shea butter 46.45 - Rapeseed oil 20.00 - Coco-caprylate / caprate mixture (Cetiol C5) 20.00 - Passiflora incarnata seed oil 5.00 - Myristyl myristate 3.00 - Beeswax 2.00 - Squalane 3.00 - Tocopherol 0.5 Phase B: - L. crispatus / maltodextrin mixture (1:1 ratio) 0.05

[0203] Heat at 75 °C with stirring to mix the components of Phase A. Once Phase A is homogeneous, add Phase B with gentle stirring at 65 °C, and then cool the mixture to ambient temperature. Composition 6 contains at least 40% (w / w) of the linear lipophilic and fat-dispersible molecules according to the present invention (20% of coco caprylate / caprate), and other linear fat-dispersible and lipophilic molecules (rapeseed oil containing 80% oleic acid; Passiflora incarnata seed oil containing at least 70% oleic acid, 7% linoleic acid, 1.4% behenic acid, 11% palmitic acid and 5% stearic acid, beeswax containing myristyl myristate and myristyl palmitate and cerotic acid (also known as hexacosanoic acid)).

[0204] The viability of the probiotic bacterial strain is monitored in the same manner as in Example 2 (see [Table 6]).

[0205]

Table 6

[0206] After storing Composition 6 containing squalane at 4 °C for 3 months, no viable bacteria are measured. The addition of 40% by weight of the linear lipophilic and dispersible molecules according to the present invention based on the total weight of the composition and 10% by weight of other linear fat-dispersible and lipophilic molecules based on the total weight of the composition makes it possible to maintain the viability of the probiotic bacterial strain. On the other hand, when more than 40% of branched-chain lipophilic and fat-dispersible molecules (shea butter + squalane) are present, a decrease of 2 logarithmic units is brought about from the third month, which reflects the decrease in viability at ambient temperature.

Claims

1. - At least one live probiotic bacterial strain, and - Dicaprylyl carbonate; capric-caprate optionally combined with caprylic-caprate, preferably a mixture of capric-caprate and capric-caprate; undecane and / or tridecane; linoleic acid and / or oleic acid and / or their linear esters and / or oleyl alcohol; behenyl alcohol and / or its acid and ester derivatives, in particular behenic acid or docosanoic acid or behenic acid ester; and / or at least one linear fat-dispersible and fat-soluble molecule selected from their mixtures, - Optionally, one or more other linear fat-dispersible and fat-soluble molecules A cosmetic and / or dermatological composition comprising, wherein the total content of the linear fat-dispersible and fat-soluble molecules is at least 40% by weight based on the total weight of the composition.

2. The other linear fat-dispersible and fat-soluble molecules are - Chemical formula C ｎ H ２ｎ＋２ (wherein, n represents a value in the range of 6 to 40) of an alkane molecule, - Chemical formula CH ３ - C ｘ H ２ｘ - COO - C ｙ H ２ｙ - CH ３ (wherein each of the exponents of x and y independently represents a value in the range of 5 to 19) an ester molecule - Chemical formula CH ３ - C ｘ H ２ｘ - An acid molecule of -C(O)OH (wherein x represents a value in the range of 5 to 24, preferably 5 to 21), for example, serotic acid - Chemical formula CH ３ - C ｘ H ２ｘ - OH (wherein x represents a value in the range of 5 to 21), and an alcohol molecule, and Any one of their mixtures The cosmetic and / or dermatological composition according to claim 1, selected from.

3. The linear fat-dispersible and fat-soluble molecules selected from dicaprylyl carbonate; capric-caprate optionally combined with caprylic-caprate, preferably a mixture of capric-caprate and capric-caprate; undecane and / or tridecane; linoleic acid and / or oleic acid and / or their linear esters and / or oleyl alcohol; behenyl alcohol and / or its acid and ester derivatives, in particular behenic acid or docosanoic acid or behenic acid ester; and / or their mixtures are present in a content of at least 8% by weight, preferably at least 10% by weight, more preferably at least 15% by weight based on the total weight of the composition. The cosmetic and / or dermatological composition according to claim 1 or 2.

4. The linear fat-dispersible and fat-soluble molecules are dicaprylyl carbonate. The cosmetic and / or dermatological composition according to any one of claims 1 to 3.

5. The selected linear fat-dispersible and fat-soluble molecules are capric-caprate optionally combined with caprylic-caprate, preferably a mixture of capric-caprate and capric-caprate. The cosmetic and / or dermatological composition according to any one of claims 1 to 4.

6. The beauty and / or dermatological composition according to any one of claims 1 to 5, wherein the selected linear fat-dispersible and fat-soluble molecule is dicaprylyl carbonate.

7. The beauty and / or dermatological composition according to any one of claims 1 to 6, wherein the selected linear fat-dispersible and fat-soluble molecule is undecane and / or tridecane.

8. The beauty and / or dermatological composition according to any one of claims 1 to 7, wherein the selected linear fat-dispersible and fat-soluble molecule is linoleic acid and / or oleic acid and / or isostearyl linoleate and / or oleyl alcohol, preferably linoleic acid.

9. The beauty and / or dermatological composition according to any one of claims 1 to 8, wherein the selected linear fat-dispersible and fat-soluble molecule is behenyl alcohol and / or its acid and ester derivatives, particularly behenic acid or docosanoic acid or behenic acid ester, preferably behenyl alcohol.

10. The linear fat-dispersible and fat-soluble molecule selected from dicaprylyl carbonate; coco-caprylate optionally combined with coco-caprate, preferably a mixture of coco-caprylate and coco-caprate; undecane and / or tridecane; linoleic acid and / or oleic acid and / or their linear esters and / or oleyl alcohol; behenyl alcohol and / or its acid and ester derivatives, particularly behenic acid or docosanoic acid or behenic acid ester; and / or mixtures thereof is present in a content of at least 40% by weight, preferably at least 50% by weight, more preferably at least 60% by weight based on the total weight of the composition, in the beauty and / or dermatological composition according to any one of claims 1 to 9.

11. Decaprylyl carbonate; coco caprate, optionally in combination with coco caprylate, preferably a mixture of coco caprylate and coco caprate; undecane and / or tridecane; linoleic acid and / or oleic acid and / or their linear esters and / or oleyl alcohol; behenyl alcohol and / or its acid and ester derivatives, in particular at least two, preferably three or four linear fat-dispersible and fat-soluble molecules selected from behenic acid or docosanoic acid or behenic acid esters, the composition according to any one of claims 1 to 10.

12. The composition according to any one of claims 1 to 11, further comprising a branched-chain fat-soluble and fat-dispersible molecule selected from octyldodecanol, propylheptyl caprylate, a mixture of caprylic triglyceride and capric triglyceride, hydrogenated castor oil, shea butter, coconut oil and / or coco glyceride.

13. The composition according to any one of claims 1 to 12, wherein the live probiotic bacterial strain is selected from Lactobacillus crispatus, Corynebacterium accolens, Sphingomonas glacialis, Streptococcus salivarius and mixtures thereof.

14. The composition according to any one of claims 1 to 13, wherein the live bacterial strain is incorporated in an amount ranging from 10% to 80% by weight, preferably from 30% to 70% by weight, more preferably from 40% to 60% by weight, based on the total weight of the powder obtained by lyophilization on a maltodextrin support.

15. The viable bacterial strain has a content of 10 ３ to 10 １５ CFU (colony forming units) per gram of the composition, and is the composition according to any one of claims 1 to 14.

16. The composition according to any one of claims 1 to 15, wherein the live bacterial strain is present in a content of 0.01% to 3% by weight based on the total weight of the composition.

17. The composition according to any one of claims 1 to 16, wherein the water activity (Aw) in the composition is less than 0.

6.

18. The composition according to any one of claims 1 to 17, characterized in that it is in the form of an oily suspension or solution, an oily cream or gel, an emulsion, water-in-oil, or multiple, or silicone type emulsion, a mask, a beauty liquid, a lotion, a solid soap, a solid shampoo, a solid foam product, a dermatological bar, an ointment, a mousse, a patch, for example in the form of a makeup powder, rod or stick, preferably in the form of a liquid, pasty or solid anhydrous product.

19. Non-therapeutic use of the cosmetic composition according to any one of claims 1 to 18 for preventing and / or reducing the appearance of aesthetically non-pleasing and / or unpleasant symptoms on healthy skin, healthy body growths and / or healthy mucous membranes, particularly sensitive or sensitized skin, body growths and / or mucous membranes, fragile or weakened skin, body growths and / or mucous membranes, dry skin, body growths and / or mucous membranes and / or skin, body growths and / or mucous membranes having an atopic tendency.

20. Non-therapeutic use of the cosmetic composition according to any one of claims 1 to 18 as a moisturizing agent and / or a soothing agent for healthy skin, healthy body growths and / or healthy mucous membranes.

21. Non-therapeutic use of the cosmetic composition according to any one of claims 1 to 18 by topical application to a site of healthy skin, mucous membrane and / or body growth selected preferably from the leg; foot; underarm; hand; thigh; waist; buttocks; waist; groin; inguinal region; abdomen; nape; neck; arm; torso; back; face; scalp; hair; nails; and / or lip mucosa, advantageously the underarm, nape, hair, nails, lip mucosa and / or face, more advantageously the face.

22. For use as an anti-inflammatory agent or antibacterial agent and / or for the treatment and / or prevention of infections of the skin and / or mucous membranes and / or body surface growths caused by pathogenic yeasts or bacteria, such as pathogenic microorganisms like S. aureus, for example mycosis, eczema, seborrheic or atopic dermatitis, acne and inflammation and / or erythema of the skin or mucous membranes caused by pathogenic yeasts or bacteria, such as pathogenic microorganisms like S. aureus, in particular for the treatment and / or prevention of diaper rash in infants and / or for the prevention and / or pharmaceutical treatment, in particular dermatological treatment, of conditions associated with reactive and / or atopic skin and / or mucous membranes, the dermatological composition according to any one of claims 1 to 18.

23. Use of at least one linear fat-dispersible and fat-soluble molecule selected from dicaprylyl carbonate; capric / caprylic acid, optionally combined with coco-caprate, preferably a mixture of capric / caprylic acid and coco-caprate; undecane and / or tridecane; linoleic acid and / or oleic acid and / or their linear esters and / or oleyl alcohol; behenyl alcohol and / or its acid and ester derivatives, in particular behenic acid or docosanoic acid or behenic acid ester; and / or mixtures thereof, and optionally one or more other linear fat-dispersible and fat-soluble molecules, wherein the total weight of the linear fat-dispersible and fat-soluble molecules is at least 40% by weight based on the total weight of the cosmetic and / or dermatological composition.

24. The use according to claim 23, characterized in that the composition is as described in any one of claims 1 to 18.

Images